Dear Editor,
We read with interest the re v i ew entitled ‘My brother has
severe sepsis. Should he receive Xigris?’ by Suter et
al.1We enjoyed the article as we fully agree with the author’s
statement that “the optimum population of patients for tre a tment
with activated human protein C (rhAPC) need to be defined
more clearly.”
